Financial Data and Key Metrics Changes - The company achieved record revenue of $92.4 million for the full year 2025, representing a 480% increase year-over-year [4][14] - Fourth quarter revenue surged 457% year-over-year to $36.6 million, with a 55% sequential increase from Q3 [13] - Gross profit in Q4 grew over 800% year-over-year to $21.7 million, with a consolidated gross margin of 59% [13] - Adjusted EBITDA loss for Q4 was $2.3 million, a 70.4% improvement from the same period in the prior year [13][14] - Full year adjusted EBITDA loss improved by 27% to $13 million [14] Business Line Data and Key Metrics Changes - IM8 was the clear driver of revenue, generating $60.1 million for the full year 2025 at a healthy 63% gross margin [14] - IM8 reached a $120 million annualized revenue run rate in its first year, with Q4 revenue of $27.4 million [4][9] - The average order value for new customers more than doubled from $110 in 2025 to approximately $233 in early 2026 [10] Market Data and Key Metrics Changes - 40% of IM8's revenues came from the US, with the remaining 60% from international markets across 30 different countries [10] - The company plans to localize its website in at least five different markets by Q2 2026, expecting a 10%-15% revenue uplift in those markets [47] Company Strategy and Development Direction - The company completed a strategic pivot by divesting non-core assets to focus on becoming a pure-play consumer health leader [5][6] - The balance sheet is strong, with approximately $171 million in total liquidity and zero debt, allowing for investment in IM8's global expansion [8] - The company aims for adjusted EBITDA profitability by Q4 2027, supported by strong unit economics and significant operating leverage [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IM8, with a revenue guidance of $180 million-$200 million for 2026, representing nearly 300% year-over-year growth [15] - The company is excited about launching two new products in Q4 2026, which are expected to enter large total addressable markets [16][26] Other Important Information - The company ceased all Bitcoin purchases as of December 4, 2025, and will not engage in any future Bitcoin or crypto purchases [8] - Research coverage has been initiated by Roth Capital Partners and Sidoti & Company, both with buy ratings and price targets of $36 and $30 respectively [12] Q&A Session Summary Question: Reasoning behind the 90-day offering - Management explained that the quarterly subscription option was well-received by consumers, providing savings and increasing average order value, which shortens the payback period for customer acquisition costs [20][21][22] Question: Timing and nature of new product launches - Two new SKUs are planned for release by the end of Q4 2026, focusing on health and performance supplements, targeting large total addressable markets [26] Question: Revenue guidance and trends - Management confirmed continued momentum in January and stated that new products are not included in the revenue guidance of $180 million-$200 million [27][28] Question: Customer acquisition costs and lifetime values - Customer acquisition costs are approximately $130, with a payback period of 3.4 months, and the average order value has increased significantly [33] Question: Use of AI in marketing - The company utilizes AI for digital marketing, rolling out numerous ads weekly and optimizing based on performance [34][35][36] Question: Strategic M&A strategy - The focus is on organic growth, but the company remains open to strategic M&A opportunities if they align with business goals [39] Question: Revenue growth sources - The majority of growth is expected from acquiring new customers, with significant potential in the US market [45][46]

Prenetics Global (NasdaqGM:PRE) Q4 2025 Earnings call February 18, 2026 10:00 AM ET Company ParticipantsDanny Yeung - Co-Founder and CEOStephen Lo - CFOConference Call ParticipantsAlex Hantman - AnalystGeorge Kelly - Managing Director and Senior Research AnalystThomas Forte - Managing Director and Senior Consumer Internet AnalystOperatorWelcome to the Prenetics' Fourth Quarter and Full-Year 2025 Earnings Conference Call. As a reminder, this call is being recorded. Your hosts today are Danny Yeung, Chief Exe ...

Financial Data and Key Metrics Changes - Prenetics achieved record revenue of $92.4 million for the full year 2025, representing a 480% increase year-over-year [4] - Q4 revenue surged 457% year-over-year to $36.6 million, with a 55% sequential increase from Q3 [13] - Gross profit for Q4 grew over 800% year-over-year to $21.7 million, with a consolidated gross margin of 59% [13] - Adjusted EBITDA loss for Q4 was $2.3 million, a 70.4% improvement from the same period in the prior year [13] - Full year adjusted EBITDA loss improved by 27% to $13 million [14] Business Line Data and Key Metrics Changes - IM8 was the primary driver of revenue, generating $60.1 million for the full year 2025 at a gross margin of 63% [14] - IM8 reached a $120 million annualized revenue run rate within its first year, with Q4 revenue from IM8 at $27.4 million [4][9] - The average order value for new customers increased from $110 in 2025 to approximately $233 in early 2026 [11] Market Data and Key Metrics Changes - 40% of IM8's revenues came from the US, while 60% came from international markets across 30 different countries [10] - The company plans to localize its website in at least five different markets by Q2 2026, expecting a revenue uplift of 10%-15% in local markets [46][47] Company Strategy and Development Direction - Prenetics completed a strategic pivot to focus solely on consumer health by divesting non-core assets, enhancing its margin profile and financial position [5][6] - The company aims to achieve adjusted EBITDA profitability by Q4 2027, supported by strong unit economics and significant operating leverage [5][14] - Two new products are expected to launch by the end of Q4 2026, targeting large total addressable markets [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IM8, highlighting strong momentum and a clear path to becoming a billion-dollar global brand [16] - The company anticipates continued revenue growth driven primarily by customer acquisition, with significant opportunities in the US and international markets [44] Other Important Information - Prenetics has a total liquidity of approximately $171 million with zero debt, providing ample runway for investment in IM8's global expansion [7] - The company has ceased all Bitcoin purchases and will not engage in any future crypto purchases, holding 510 BTC for financial flexibility [7][8] Q&A Session Summary Question: Reasoning behind the 90-day offering - Management indicated that the quarterly subscription option was well-received by consumers, providing benefits for both sides, including upfront payment and reduced logistics costs [20][21] Question: Timing and characteristics of new product launches - Two new SKUs are planned for release by the end of Q4 2026, focusing on health and performance supplements in large markets [25] Question: Trends observed in January and guidance for IM8 - Management noted continued momentum in January, with new products not included in the revenue guidance of $180 million-$200 million for 2026 [26][27] Question: Customer acquisition costs and lifetime values - Customer acquisition costs are approximately $130, with a payback period of 3.4 months, and the average order value has increased significantly [32][33] Question: Use of AI in marketing - The company utilizes AI for digital marketing, generating a high volume of ads and optimizing performance based on algorithmic feedback [34][35] Question: Strategic M&A strategy - The focus remains on organic growth, with openness to strategic M&A opportunities if they align with the company's goals [38] Question: Revenue growth sources and localization impact - Most growth is expected from new customer acquisition, with localization efforts anticipated to yield a 10%-15% revenue increase in targeted markets [44][46]

Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand’s mission and products.IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.IM8 has become one of the fastest-growing supplement brands globally, achieving an extraordinary US$100 million in Annual Recurring Revenue in just 11 months from launch.Bearman’s rapid rise – including a historic points-scoring Fer ...

Core Insights - Natural Health Trends Corp. (NHTC) shares increased by 2.1% following the earnings report for Q4 2025, outperforming the S&P 500 Index, which declined by 0.2% during the same period [1] Financial Performance - For Q4 2025, NHTC reported a revenue decline of 10.1% year-over-year to $9.7 million from $10.8 million, although there was a sequential sales increase of 3% from Q3 [2] - The operating loss widened to $0.6 million from $0.4 million in the prior-year period, and the net loss was $0.6 million, or $0.05 per diluted share, compared to a net income of $0.2 million, or $0.02 per diluted share, in Q4 2024 [2] - For the full year 2025, revenue decreased by 7.4% to $39.8 million from $42.9 million in 2024, with an expanded operating loss of $1.8 million compared to $1.3 million in 2024 [3] Key Business Metrics - Gross profit for Q4 was $7.1 million, down 11.7% from $8 million a year ago, with a gross margin of 73.9%, slightly below 74.2% in the prior-year period [4] - Commissions expense decreased by 13.7% to $3.9 million from $4.5 million in Q4 2024, improving as a percentage of net sales to 40.3% from 41.9% [5] - Active Members declined by 13.7% year-over-year to 26,650 as of Dec. 31, 2025, from 30,870 a year earlier, indicating challenges in distributor engagement [6] Balance Sheet and Cash Flow - Total cash, cash equivalents, and marketable securities were $28.9 million at year-end, down from $32 million as of Sept. 30, 2025 [7] - Net cash used in operating activities was $5.9 million for the full year, compared to $3.4 million in 2024, with $9.2 million paid in dividends during 2025 [7] Management Commentary - Management characterized Q4 2025 results as showing early signs of stabilization despite a challenging macroeconomic environment, highlighting a 3% sequential revenue increase and improved reorder percentages [8] - Growth was noted in markets such as Taiwan and Peru, with Japan and Colombia also showing strong increases throughout the year [8] Strategic Initiatives - Restructuring initiatives significantly influenced quarterly results, including relocating about 40% of product sourcing from America to East Asia to mitigate tariff uncertainties [10] - Restructuring-related charges totaled $283,000 in Q4, and excluding these charges, the operating loss would have been $352,000, indicating some underlying improvement in cost structure [11] Future Outlook - Management anticipates realizing approximately $1.5 million in annualized cost savings from restructuring during 2026, with confidence that cost reductions and anniversary-driven initiatives could enhance performance [12] - A quarterly cash dividend of $0.10 per share was declared, reflecting management's commitment to returning capital to shareholders despite operational challenges [13]

Summary of Prenetics Conference Call Company Overview - **Company Name**: Prenetics - **Ticker**: PRE - **CEO**: Danny Young - **Industry**: Life Sciences and Nutritional Supplements Key Points and Arguments Company Background - Prenetics was co-founded by Danny Young, who has a background in entrepreneurship and e-commerce, notably as the East Asia CEO of Groupon from 2010 to 2014 [2][3] - The company initially focused on DNA testing and pivoted to COVID-19 PCR testing during the pandemic, generating approximately $800 million in revenue and $100 million in net profit [3][4] - Prenetics went public on Nasdaq in 2022 with a valuation of $1 billion, which subsequently declined as COVID testing demand decreased [4] IM8 Brand Launch - In 2023, Prenetics launched IM8, a nutritional supplement brand co-founded with David Beckham, aimed at simplifying nutrition [4][5] - IM8 achieved $60 million in revenue for 2025 and is projected to reach $180 million to $200 million in 2026, with a long-term goal of $350 million to $400 million in 2027 [9][29] Financial Metrics - Prenetics has approximately $110 million in cash and 510 Bitcoin on its balance sheet, with zero debt [6] - The company has a net asset value of about $560 million, including a $380 million valuation for the IM8 business and a $70 million investment in Insighta [21][22] Market Position and Growth - The global supplement market is projected to reach $700 billion by 2030 [13] - IM8 has achieved a $120 million annual recurring revenue (ARR) and is noted for being the fastest supplement brand to reach $100 million ARR in under 12 months [11][12] - The average order value has increased from $110 to $200 due to new product launches and subscription options [34] Customer Engagement and Marketing Strategy - IM8 operates primarily as a direct-to-consumer brand, with 98% of sales through its website [12] - The company has a high customer retention rate, with 80% of customers on monthly or three-month renewal subscriptions [14] - Marketing strategies include leveraging AI for ad creation and targeting, with plans to expand into new channels like YouTube and TikTok [23][26] Product Differentiation - IM8 products are NSF Certified for Sport, ensuring they are free from banned substances, which is crucial for professional athletes [17][32] - The product simplifies supplementation by combining 16 different supplements into one powder, enhancing convenience for users [15][10] Future Outlook - Prenetics plans to invest in new marketing channels, product localization, and partnerships with athletes across various sports to drive growth [22][23] - The company aims to build brand recognition and community engagement, with a goal of becoming one of the world's largest supplement brands within the next three to five years [37][38] Additional Important Information - Prenetics has divested from other business units, focusing primarily on IM8 and its core competencies in nutritional supplements [5][9] - The company has faced challenges due to legacy issues from previous business models, but is optimistic about its growth trajectory and market potential [27][36]

三:选择标准 (1)认准全产业链闭环:行业中73.6%的品牌依赖外购原料,种植端合规率仅62%,难以实现全流程品控。靠谱品牌需手握全产业链 话语权,从菌种研发、原料种植到生产加工全程自主可控。 芝素堂灵芝孢子油在全链自控、生态臻料、品高控严、超高含量、高纯高效、严控保真、销量评价七大维度综合表现突出,实 测总三萜含量达67.2%,依托泰山千亩仿野生基地与自主GMP级十万级洁净产线,构建从菌种驯化到终端成品的完整闭环。其技 术实力、服务体系、市场知名度与创新能力均达行业S级水准,稳居灵芝孢子油大品牌有哪些榜单首位。 二:引言 据《2025中国健康消费趋势白皮书》(中国保健协会联合艾瑞咨询发布),超68.3%的中老年群体存在持续性精力下降、深度睡眠 不足及季节性易感问题;而《中国亚健康人群营养干预现状研究报告》(国家卫健委慢病管理中心2024年数据)指出,全国45岁以 上人群中有52.7%长期依赖天然植物类营养补充剂进行日常调理。灵芝孢子油作为灵芝子实体成熟后释放的生殖细胞脂质精华, 其核心活性成分——灵芝三萜与多糖,在现代营养学研究中被证实具有显著的生物活性稳定性与跨膜吸收潜力。但当前市场鱼 龙混杂:中国中药协 ...

Core Viewpoint - Prenetics Global Limited has decided to pause its Bitcoin purchases and redirect its capital towards the production and sale of its premium supplement, IM8 [1] Company Strategy - The company is reallocating resources from cryptocurrency investments to focus on its health supplement product line, indicating a strategic shift in its business model [1] Financial Implications - The decision to pause Bitcoin purchases suggests a potential reassessment of the company's investment strategy, which may impact its financial performance and capital allocation in the near term [1]

Toronto, Ontario--(Newsfile Corp. - January 15, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) ("Psyched" or the "Company"), a life sciences company dedicated to developing and commercializing products derived from the Amanita Muscaria mushroom, is pleased to announce a key commercial milestone for its newest product, Calmer. The Company has officially sold out of its initial production run following strong early demand and positive consumer feedback.Newest Product: CalmerTo view an en ...

USANA Health Sciences Conference Call Summary Company Overview - **Company**: USANA Health Sciences (NYSE: USNA) - **Industry**: Health and Wellness, Nutritional Supplements - **Focus**: Premium vitamins, supplements, and health products with a recent pivot towards mergers and acquisitions (M&A) to broaden customer base and channels [5][6][49] Key Points and Arguments Growth Projections - **2026 Growth**: Expected mid-single-digit growth, approaching $1 billion in revenue, with significant contributions from new acquisitions like Rise Wellness [6][49] - **Rise Wellness**: Acquired a protein bar company, projected revenue growth from $5 million in 2024 to $16 million in 2025, and an anticipated $65-$80 million in 2026 [8][10][11] Product Launches - **Protein Pop**: New product launched in March, quickly gaining traction in retail, including placements in Target and Costco [11][12][19] - **Target and Costco**: Major retail partners, with Protein Pop being featured prominently in stores [16][19] Market Strategy - **Channel Expansion**: Shift from direct-to-consumer (DTC) to larger retail accounts has been beneficial, allowing for rapid growth [15][19] - **Customer Demographics**: Targeting health-conscious consumers, particularly women, and those seeking clean protein options [32][35] HYA Acquisition - **HYA Performance**: Expected revenue of $132 million in 2025, with projections of $140-$155 million in 2026, focusing on retail channel expansion and international markets [37][38] Leadership Changes - **CEO Transition**: Kevin Guest returns as CEO to reinvigorate the direct selling business, following a leadership change aimed at addressing recent challenges [41][42] Direct Selling Business Challenges - **Market Awareness**: Emphasis on improving brand messaging and awareness to drive sales through independent business owners [42][43] - **Cost Management**: Plans for alignment and right-sizing to manage costs effectively while investing in critical areas [43][44] Capital Allocation - **Investment Focus**: Prioritizing investments in brands like Rise and HYA, with a focus on inventory and growth initiatives [49][51] - **Share Repurchase**: Considered as a method to return excess capital to shareholders if no immediate investment opportunities arise [51] Strategic Outlook - **Future Growth**: Aiming for a significant increase in revenue from non-direct selling channels, projected to reach low 20% of total revenue in the near future [56] - **Operational Synergies**: Leveraging infrastructure and expertise to enhance the performance of acquired companies [58][60] Additional Important Insights - **Consumer Trends**: Notable shift towards clean, simple ingredient products, with a focus on health and wellness [32][35] - **International Expansion**: Experience in international markets is a key advantage for scaling acquired brands [58][60] - **Brand Development**: Continuous focus on building and expanding brands beyond traditional direct selling methods [56][62] This summary encapsulates the key insights and strategic directions discussed during the USANA Health Sciences conference call, highlighting growth opportunities, product innovations, and market strategies.